Drugs / VNA-318
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06721091 | Dec 2024 → Nov 2025 | — | VANDRIA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | VANDRIA | Results New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases vandria.com ↗
The newly presented results for pre-specified endpoints include pharmacodynamic effects in the human brain following 12 days of dosing with VNA-318, assessed using quantitative electroencephalography (qEEG), and direct measurement of VNA-318 concentrations in cerebrospinal fluid (CSF), confirming brain penetration and activity consistent with preclinical studies. |
| 2025-12-02 | VANDRIA | Results Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease vandria.com ↗
Vandria SA, a clinical stage biotech company developing small molecule therapeutics to restore mitochondrial function and reduce inflammation for the treatment of age-related and chronic diseases, today announces topline results from its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNA-318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06721091 ↗ |
| Route | Oral | “VNA-318, administered orally” NCT06721091 ↗ |